We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HealthEquity (HQY) Up 4% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for HealthEquity (HQY - Free Report) . Shares have added about 4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is HealthEquity due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
HealthEquity Q3 Earnings and Revenues Beat Estimates
HealthEquity, Inc. reported adjusted earnings per share of 41 cents in third-quarter fiscal 2021, which beat the Zacks Consensus Estimate of 35 cents by 17.1%. However, the bottom line fell 4.7% on a year-over-year basis.
Revenues in Detail
Thecompany generated revenues of $179.4 million, outpacing the Zacks Consensus Estimate by 1.9%. Also the top line rose 14.2% from the prior-year quarter.
HSA Details
As of Oct 31, 2020, the total number of Health Savings Accounts (HSA) for which HealthEquity served as a non-bank custodian (HSA members), came in at5.5 million, up 9% year over year.
Additionally, total Active HSA assets were $12.4 billion, up 19% year over year.
Total Accounts including HSAs and complementary consumer directed benefits (CDB) accounts summed 12.5 million, flat year over year.
Segmental Performance
Service Revenues: Revenues of$104.6 million were up 19.4% from the year-ago figure.
Custodial Revenues: Revenues grew 3.4% year over year to $48.5 million.
Interchange Revenues: Revenues increased16.4% year over year to $26.2 million.
Margin Details
HealthEquity generated gross profit of $104.6 million, up 8.8% from the year-ago quarter. Gross margin was 58.3% of net revenues, down 282 basis points (bps) year over year.
Adjusted operating profit in the fiscal third quarter was $38.8 million, down 4.5% year over year. Adjusted operating margin was 21.6% in the period, contracting 423 bps year over year.
Financial Position
The company exited the fiscal third quarter with cash and cash equivalents of $299.4 million compared with $268.9 million at the end of the fiscal second quarter.
Cumulative cash flow from operating activities in the third quarter came in at $120.7 million, up from $74.1 million in the year-ago period.
Full-Fiscal View
For fiscal 2021, revenues are projected within $725-$731 million (up from the previously guided range of $720-$730 million). The Zacks Consensus Estimate for the sameis pegged at $728.2 million.
Adjusted earnings per share are expected within $1.55-$1.61 (up from the earlier issued range of $1.48-$1.58). The Zacks Consensus Estimate for the same stands at $1.56.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -14.54% due to these changes.
VGM Scores
At this time, HealthEquity has an average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, HealthEquity has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HealthEquity (HQY) Up 4% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for HealthEquity (HQY - Free Report) . Shares have added about 4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is HealthEquity due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
HealthEquity Q3 Earnings and Revenues Beat Estimates
HealthEquity, Inc. reported adjusted earnings per share of 41 cents in third-quarter fiscal 2021, which beat the Zacks Consensus Estimate of 35 cents by 17.1%. However, the bottom line fell 4.7% on a year-over-year basis.
Revenues in Detail
Thecompany generated revenues of $179.4 million, outpacing the Zacks Consensus Estimate by 1.9%. Also the top line rose 14.2% from the prior-year quarter.
HSA Details
As of Oct 31, 2020, the total number of Health Savings Accounts (HSA) for which HealthEquity served as a non-bank custodian (HSA members), came in at5.5 million, up 9% year over year.
Additionally, total Active HSA assets were $12.4 billion, up 19% year over year.
Total Accounts including HSAs and complementary consumer directed benefits (CDB) accounts summed 12.5 million, flat year over year.
Segmental Performance
Service Revenues: Revenues of$104.6 million were up 19.4% from the year-ago figure.
Custodial Revenues: Revenues grew 3.4% year over year to $48.5 million.
Interchange Revenues: Revenues increased16.4% year over year to $26.2 million.
Margin Details
HealthEquity generated gross profit of $104.6 million, up 8.8% from the year-ago quarter. Gross margin was 58.3% of net revenues, down 282 basis points (bps) year over year.
Adjusted operating profit in the fiscal third quarter was $38.8 million, down 4.5% year over year. Adjusted operating margin was 21.6% in the period, contracting 423 bps year over year.
Financial Position
The company exited the fiscal third quarter with cash and cash equivalents of $299.4 million compared with $268.9 million at the end of the fiscal second quarter.
Cumulative cash flow from operating activities in the third quarter came in at $120.7 million, up from $74.1 million in the year-ago period.
Full-Fiscal View
For fiscal 2021, revenues are projected within $725-$731 million (up from the previously guided range of $720-$730 million). The Zacks Consensus Estimate for the sameis pegged at $728.2 million.
Adjusted earnings per share are expected within $1.55-$1.61 (up from the earlier issued range of $1.48-$1.58). The Zacks Consensus Estimate for the same stands at $1.56.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -14.54% due to these changes.
VGM Scores
At this time, HealthEquity has an average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, HealthEquity has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.